NCT02472236View on ClinicalTrials.gov

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 8, 2015

Primary Completion Date

September 24, 2015

Study Completion Date

January 18, 2016

Conditions
Healthy
Interventions
DRUG

PEX168

200µg,injected subcutaneously,once a week.

DRUG

Digoxin

0.5mg,oral,two times.

Trial Locations (1)

710061

The first affiliate of Xi'an Jiaotong University, Xi’an

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY